DNA-Guided chemo aims to stop colon cancer return

NCT ID NCT05062889

Terminated Disease control Sponsor: Gruppo Oncologico del Nord-Ovest Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether using a blood test for circulating tumor DNA (ctDNA) can help doctors decide if patients with stage II or III colon cancer need stronger chemotherapy after surgery. The trial compares standard chemo with a more intense regimen (FOLFOXIRI) and an additional drug (Trifluridine/Tipiracil) for those still at high risk. A separate group with HER2-positive cancer will receive targeted therapy. The goal is to see if these approaches can make ctDNA undetectable, which may lower the chance of cancer coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

chemotherapy (FOLFOXIRI, FOLFOX, Trifluridine/Tipiracil, Trastuzumab, Tucatinib)

What this could lead to

If successful, this could show that using ctDNA to guide more aggressive chemotherapy reduces the chance of colon cancer returning after surgery.

What could go wrong

This is a phase 2 trial that is currently suspended, so results are far from certain. The intensified chemo may cause more side effects and may not improve long-term outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm colorectal cancer malignant colon neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-POSITIVE COLON CANCER RAS WILD-TYPE COLON CANCER STAGE II COLON CANCER STAGE III COLON CANCER

Contacts and locations

Show contact details

Locations

A.O.U Careggi

Florence, 50134, Italy
A.O.U. di Ferrara Arcispedale Sant'Anna

Ferrara, 44100, Italy
AOU Cagliari PO Policlinico Universitario Duilio Casula Presidio Policlinico Universitario "Duilio Casula"

Cagliari, 09042, Italy
AUSL Romagna

Ravenna, 48121, Italy
Azienda Ospedaliera Cardinale Giovanni Panico

Tricase, Lecce, 73039, Italy
Azienda Ospedaliero Universitaria Maggiore della Carita

Novara, 28100, Italy
Azienda Sanitaria Universitaria Friuli Centrale

Udine, 33100, Italy
Azienda USL IRCCS di Reggio Emilia (centro principale Reggio Emilia e centro satellite Guastalla).

Reggio Emilia, 42123, Italy
Azienda USL Toscana Nord Ovest di Livorno

Livorno, 57124, Italy
Azienda USL di Piacenza

Piacenza, 29121, Italy
E.O. Ospedali Galliera di Genova

Genova, 16128, Italy
Fondazione Casa Sollievo della Sofferenza

San Giovanni Rotondo, Foggia, 71013, Italy
Fondazione IRCCS INT - Milano

Milan, 20133, Italy
Fondazione POLIAMBULANZA ISTITUTO OSPEDALIERO

Brescia, 25124, Italy
IRCCS di Candiolo

Torino, 10060, Italy
Istituto Oncologico Veneto IOV - IRCCS

Padua, 35128, Italy
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"

Meldola, 47014, Italy
Istituto per la ricerca sui tumori Regina Elena

Roma, 00144, Italy
Nuovo Ospedale di Prato

Prato, 59100, Italy
Ospedale Campostaggia Poggiponsi

Siena, 53100, Italy
Ospedale Fatebenefratelli Isola Tiberina

Roma, 00186, Italy
Ospedale Misericordia di Grosseto

Grosseto, 58100, Italy
Ospedale San Donato di Arezzo

Arezzo, 52100, Italy
Ospedale San Luca di Lucca

Lucca, 55100, Italy
Ospedale San Raffaele

Milan, 20132, Italy
Policlinico Fondazione Agostino Gemelli

Roma, 00168, Italy
Policlinico Tor Vergata Roma

Roma, 00133, Italy
Spedali Civili di Brescia

Brescia, 25123, Italy